Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 6 of 18 for:    marijuana | Recruiting, Not yet recruiting, Active, not recruiting, Enrolling by invitation Studies | ( Map: Colorado, United States )

The Influence of in Utero Cannabis Exposure on Neonatal Brain Morphology and Structural Connectivity

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03718520
Recruitment Status : Recruiting
First Posted : October 24, 2018
Last Update Posted : April 17, 2019
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
University of Colorado, Denver

Tracking Information
First Submitted Date October 22, 2018
First Posted Date October 24, 2018
Last Update Posted Date April 17, 2019
Actual Study Start Date November 7, 2018
Estimated Primary Completion Date July 31, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: October 24, 2018)
  • region specific grey matter volume (mm^2) in the PFC and limbic regions [ Time Frame: 2 weeks postnatal age ]
    region specific volume (mm^2)
  • structural integrity measured by fractional anisotrophy of white matter tracks that connect the PFC and limbic regions [ Time Frame: 2 weeks postnatal age ]
    mean fractional anisotrophy
Original Primary Outcome Measures
 (submitted: October 22, 2018)
Infant brain imaging [ Time Frame: 2 weeks postpartum ]
Structural metrics of the infant brain
Change History Complete list of historical versions of study NCT03718520 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures
 (submitted: November 12, 2018)
Negative affectivity based on a subscale from the Infant Behavioral Questionnaire (Rothbart, 1981) [ Time Frame: 1 year postpartum ]
Four subscales on the IBQ-R will be combined to form a negative affectivity scale including scales of Sadness, Distress to Limitations, Fear, and Falling Reactivity/Rate of Recovery from Distress.
Original Secondary Outcome Measures
 (submitted: October 22, 2018)
Infant neurobehavioral assessments [ Time Frame: 1 year postpartum ]
Aspects of infant behavior related to "effortful control" (EC).
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title The Influence of in Utero Cannabis Exposure on Neonatal Brain Morphology and Structural Connectivity
Official Title The Influence of in Utero Cannabis Exposure on Neonatal Brain Morphology and Structural Connectivity
Brief Summary Cannabis is the most commonly used drug by women during pregnancy with an estimated prevalence of use in Colorado of 5.7%. THC and its metabolites freely cross the placenta and blood-brain barrier to bind with cannabinoid receptors, disrupting the endogenous cannabinoid signaling system during a critical period of development of cortical circuitry structure and function. The density of cannabinoid receptors in the developing brain is high, especially in the limbic areas and prefrontal lobes. Research in animal models suggests synaptic plasticity in the prefrontal lobes as well the amygdala and hippocampus are impacted by the prenatal cannabis exposure; regions associated with both cognitive and emotional control, thus influencing long-term deficiencies in attention and impulsivity. This pilot study will collect preliminary data on the structural impact of in utero cannabis exposure on region-specific morphology and structural connectivity of white matter tracts that connect to the prefrontal lobes and the limbic regions shortly after birth, before confounding by the postnatal environment becomes a major influence.
Detailed Description

Cannabis is the most commonly used psychoactive substance among pregnant women, with an estimated prevalence of use between 5 to 20% in in the United States. Little is known about the neurodevelopmental consequences for the fetus, particularly in the context of contemporary cannabis use patterns including high potency strains, cannabinoids and novel routes of administration. Colorado leads the nation in implementation of legalized medical and retail marijuana. Coupled with a growing pro-marijuana advocacy movement, marijuana may be perceived as "safe" to use during pregnancy. The local actions of endocannabinoids are in place in the placenta during fetal brain development and THC and its metabolites freely pass the placental barrier and the fetal blood-brain barrier. Furthermore, cannabinoid receptors appear to be more widespread in the fetal and neonatal prefrontal cortex (PFC) and the limbic areas (the amygdala and hippocampus) than in the adult brain, thus the in utero period may be a sensitive period of human brain development during which exogenous cannabinoids could permanently alter neurodevelopmental processes. Human epidemiologic studies across diverse populations have reported an emerging theme of deficiencies related to impulse control and executive functioning among offspring with in utero exposure to cannabis starting in adolescence. Only rudimentary aspects of executive function are present in infants, thus evidence of an impact during infancy and the toddler years is sparse, inconsistent and confounded by the postnatal environment (i.e., daycare, caregiver functioning). Research is needed to evaluate the proximal impact of in utero cannabis exposure on robust metrics of neonatal brain morphology and structural integrity of white matter tracts that connect to the PFC and the limbic regions before the influence of postnatal exposures become a major confounding influence.

To address this challenge, a pilot prospective pre-birth cohort study will be conducted to investigate the impact of chronic in utero cannabis exposure by enrolling 110 mother-infant pairs (50 exposed and 60 unexposed controls) for a neonate neuroimaging scan within 2 weeks after birth. Chronic in utero cannabis exposure will be quantified using ultra-high performance liquid chromatography-tandem mass spectrometry (LC-MS) of neonatal meconium. The associations between in utero cannabis exposure and neural morphological outcomes will be examined by structural MRI and diffusion tensor imaging (DTI). The central hypothesis is that in utero cannabis exposure will be associated with alterations in grey and white matter development in the prefrontal lobe and its connectivity to limbic regions.

Specific Aim 1: To determine the magnitude of the association between in utero exposure to cannabis and neonate brain morphology and structural connectivity.

Hypothesis: In utero exposure to cannabis (assessed by THC metabolites in meconium) will be associated with the following neonate brain structural outcomes: (1) Grey matter: reduced volume in the PFC and limbic regions (i.e. the amygdala, hippocampus); (2) White matter: reduced structural integrity (assessed by fractional anisotropy) of white matter tracts that connect to the PFC and the limbic regions including the uncinate fasciculus and the cingulum bundle. The associations will be independent of other maternal substance use (i.e. tobacco), postnatal feeding practices (i.e. breastfeeding), socio-demographic characteristics and maternal mental health.

Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Retention:   Samples Without DNA
Description:
Maternal urine at 28-36 weeks gestation; maternal plasma and urine at delivery; neonate urine, meconium, cord blood and cord segment shortly after birth; maternal urine at 2 weeks postpartum; maternal urine at 1 year postpartum
Sampling Method Non-Probability Sample
Study Population This will be an observational, pre-birth prospective pilot study of 110 mother-infant pairs (50 with prenatal cannabis exposure and 60 unexposed pairs) who deliver at two academic medical centers in the Denver Metro area of Colorado (Denver Health Medical Center and the University of Colorado Hospital at Anschutz. Unexposed controls will be frequency matched to exposed cases by maternal education level. To isolate the influence of cannabis exposure, mothers using tobacco, alcohol or other drugs during pregnancy will be excluded.
Condition
  • Cannabis Use Disorder
  • PREG1
  • Drug Use
  • Fetal Exposure During Pregnancy
  • Neurodevelopmental Abnormality
Intervention Other: no intervention, this is a purely observational study
No intervention
Study Groups/Cohorts
  • prenatal exposed to cannabis
    50 mother-infant pairs with self-reported maternal chronic cannabis use during pregnancy
    Intervention: Other: no intervention, this is a purely observational study
  • prenatal not-exposed to cannabis
    60 mother-infant pairs with no self-reported maternal cannabis use during pregnancy
    Intervention: Other: no intervention, this is a purely observational study
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Recruiting
Estimated Enrollment
 (submitted: October 22, 2018)
220
Original Estimated Enrollment Same as current
Estimated Study Completion Date July 31, 2020
Estimated Primary Completion Date July 31, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • pregnant women who are receiving prenatal care at the University of Colorado Hospital at Anschutz (UCH) or Denver Health Medical Center.
  • maternal positive urine toxicology screen for cannabis at any clinical prenatal visit or self-report of cannabis during pregnancy at a clinical visit
  • greater than ≥ 28 weeks gestation,
  • aged ≥18 years,
  • expecting a singleton birth,
  • live in Colorado, and plan to deliver at UCH or Denver Health Medical Center .
  • Inclusion criteria for unexposed controls will be identical to that of exposed cases with the exception that they cannot have a positive toxicology screen for cannabis or self-reported cannabis use during pregnancy.

Exclusion Criteria (for unexposed cases and controls):

  • use of tobacco, alcohol or other drugs during pregnancy,
  • serious chronic diseases (cancer, psychiatric diseases, steroid-dependent asthma, pre-existent diabetes mellitus of any kind),
  • mothers who subsequently experience a fetal death or deliver a premature infant (< 37 weeks of gestation).
  • Postnatal exclusions will include failure to collect meconium samples at birth, infant neurological trauma, other neurological conditions in the infant (e.g., epilepsy),
  • suspicion of metal in body or other MRI contraindications in either the mother or infant.
Sex/Gender
Sexes Eligible for Study: Female
Gender Based Eligibility: Yes
Gender Eligibility Description: This study plans to enroll pregnant women.
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers Not Provided
Contacts
Contact: Tessa Crume, PhD, MSPH 3037244452 tessa.crume@ucdenver.edu
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT03718520
Other Study ID Numbers 18-0004
R21DA043833 ( U.S. NIH Grant/Contract )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement
Plan to Share IPD: No
Plan Description: A completely de-identified dataset will be created and may be shared upon PI-agreement ad development of data sharing agreements.
Responsible Party University of Colorado, Denver
Study Sponsor University of Colorado, Denver
Collaborators National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Tessa Crume, PhD, MSPH University of Colorado, Colorado School of Public Health
PRS Account University of Colorado, Denver
Verification Date April 2019